Asiri S Abeyagunawardena1, Umeshi Karunadasa2, Heshan Jayaweera2, Shenal Thalgahagoda2, Sampath Tennakoon3, Shamali Abeyagunawardena4. 1. Department of Paediatrics, Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka. asiriabey26@gmail.com. 2. Department of Paediatrics, Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka. 3. Department of Community Medicine, University of Peradeniya, Peradeniya, Sri Lanka. 4. Outpatient Department, Teaching Hospital Peradeniya, Peradeniya, Sri Lanka.
Abstract
OBJECTIVE: Levamisole (LEV) has been used successfully on an alternate-day regime of 2.5 mg/kg in steroid-dependant nephrotic syndrome (SDNS) to maintain remission. This pilot study was carried out between 2010 and 2015 at a single center in Sri Lanka to evaluate the efficacy of LEV prescribed at 2.5 mg/kg daily, which is double the alternate-day dose. METHODS: Sequential children with SDNS, relapsing more than twice in the preceding 12 months and previously treated with LEV and low-dose alternate-day prednisolone (0.1-0.6 mg/kg) were recruited to the study. This group received LEV (2.5 mg/kg) daily with the same dose of alternate-day prednisolone for 1 year. Urine protein excretion was recorded by parents on a daily basis, and the presence of 3+ proteinuria on 3 consecutive days was considered a relapse. Full blood counts and liver function tests were performed every 3 months to monitor for adverse effects. RESULTS: Sixty-four children were enrolled into the study; six were excluded due to prescription of other immunosuppressive drugs. Median age was 7.9 years; 33 were boys. The number of relapse episodes was 163 [mean per patient 2.8 ± standard deviation (SD) 0.8] in patients on alternate-day LEV and 77 (mean 1.3 ± SD 0.9) for those on daily LEV during the 12-month period of observation. The P value 0.000 (according to the Wilcoxon signed-rank test) was <0.001. No major adverse events were noted. CONCLUSIONS: The prescription of daily LEV is effective and safe for maintaining SDNS remission.
OBJECTIVE:Levamisole (LEV) has been used successfully on an alternate-day regime of 2.5 mg/kg in steroid-dependant nephrotic syndrome (SDNS) to maintain remission. This pilot study was carried out between 2010 and 2015 at a single center in Sri Lanka to evaluate the efficacy of LEV prescribed at 2.5 mg/kg daily, which is double the alternate-day dose. METHODS: Sequential children with SDNS, relapsing more than twice in the preceding 12 months and previously treated with LEV and low-dose alternate-day prednisolone (0.1-0.6 mg/kg) were recruited to the study. This group received LEV (2.5 mg/kg) daily with the same dose of alternate-day prednisolone for 1 year. Urine protein excretion was recorded by parents on a daily basis, and the presence of 3+ proteinuria on 3 consecutive days was considered a relapse. Full blood counts and liver function tests were performed every 3 months to monitor for adverse effects. RESULTS: Sixty-four children were enrolled into the study; six were excluded due to prescription of other immunosuppressive drugs. Median age was 7.9 years; 33 were boys. The number of relapse episodes was 163 [mean per patient 2.8 ± standard deviation (SD) 0.8] in patients on alternate-day LEV and 77 (mean 1.3 ± SD 0.9) for those on daily LEV during the 12-month period of observation. The P value 0.000 (according to the Wilcoxon signed-rank test) was <0.001. No major adverse events were noted. CONCLUSIONS: The prescription of daily LEV is effective and safe for maintaining SDNS remission.
Authors: Khemchand N Moorani; Aasia Mohammad Zubair; Nanga Ram Veerwani; Harnam Jaichand Hotchandani Journal: Pak J Med Sci Date: 2020 Sep-Oct Impact factor: 1.088
Authors: Bilal Aoun; Mohammad Alali; Jad A Degheili; Sami Sanjad; Claudine Vaquin; Jean Donadieu; Tim Ulinski; Salah Termos Journal: J Med Case Rep Date: 2018-07-16
Authors: Floor Veltkamp; Djera H Khan; Christa Reefman; Susan Veissi; Hedy A van Oers; Elena Levtchenko; Ron A A Mathôt; Sandrine Florquin; Joanna A E van Wijk; Michiel F Schreuder; Lotte Haverman; Antonia H M Bouts Journal: BMJ Open Date: 2019-08-01 Impact factor: 2.692
Authors: Rasmus Ehren; Marcus R Benz; Paul T Brinkkötter; Jörg Dötsch; Wolfgang R Eberl; Jutta Gellermann; Peter F Hoyer; Isabelle Jordans; Clemens Kamrath; Markus J Kemper; Kay Latta; Dominik Müller; Jun Oh; Burkhard Tönshoff; Stefanie Weber; Lutz T Weber Journal: Pediatr Nephrol Date: 2021-06-06 Impact factor: 3.714